These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 15804173

  • 1. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
    Varma MV, Sateesh K, Panchagnula R.
    Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
    [Abstract] [Full Text] [Related]

  • 2. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
    Dahan A, Amidon GL.
    Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
    [Abstract] [Full Text] [Related]

  • 3. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
    Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM.
    Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
    [Abstract] [Full Text] [Related]

  • 4. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
    Panchagnula R, Bansal T, Varma MV, Kaul CL.
    Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
    [Abstract] [Full Text] [Related]

  • 5. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW.
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
    [Abstract] [Full Text] [Related]

  • 6. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs 1. Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples.
    Varma MV, Sarkar M, Kapoor N, Panchagnula R.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb 25; 816(1-2):243-9. PubMed ID: 15664356
    [Abstract] [Full Text] [Related]

  • 7. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ.
    Varma MV, Panchagnula R.
    J Pharm Sci; 2005 Dec 25; 94(12):2632-43. PubMed ID: 16258992
    [Abstract] [Full Text] [Related]

  • 8. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
    Jain R, Agarwal S, Majumdar S, Zhu X, Pal D, Mitra AK.
    Int J Pharm; 2005 Oct 13; 303(1-2):8-19. PubMed ID: 16137847
    [Abstract] [Full Text] [Related]

  • 9. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability.
    Varma MV, Panchagnula R.
    J Pharm Sci; 2005 Aug 13; 94(8):1694-704. PubMed ID: 15986467
    [Abstract] [Full Text] [Related]

  • 10. Impact of P-glycoprotein on clopidogrel absorption.
    Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E.
    Clin Pharmacol Ther; 2006 Nov 13; 80(5):486-501. PubMed ID: 17112805
    [Abstract] [Full Text] [Related]

  • 11. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
    Sharma P, Varma MV, Chawla HP, Panchagnula R.
    Farmaco; 2005 Nov 13; 60(11-12):874-83. PubMed ID: 16243320
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique.
    Fortuna A, Alves G, Falcão A, Soares-da-Silva P.
    Epilepsia; 2012 Mar 13; 53(3):529-38. PubMed ID: 22372629
    [Abstract] [Full Text] [Related]

  • 13. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
    Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I.
    Drug Metab Dispos; 2006 May 13; 34(5):793-9. PubMed ID: 16455807
    [Abstract] [Full Text] [Related]

  • 14. P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.
    Acharya P, Tran TT, Polli JW, Ayrton A, Ellens H, Bentz J.
    Biochemistry; 2006 Dec 26; 45(51):15505-19. PubMed ID: 17176072
    [Abstract] [Full Text] [Related]

  • 15. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
    Cao X, Yu LX, Barbaciru C, Landowski CP, Shin HC, Gibbs S, Miller HA, Amidon GL, Sun D.
    Mol Pharm; 2005 Dec 26; 2(4):329-40. PubMed ID: 16053336
    [Abstract] [Full Text] [Related]

  • 16. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
    Collett A, Higgs NB, Sims E, Rowland M, Warhurst G.
    J Pharmacol Exp Ther; 1999 Jan 26; 288(1):171-8. PubMed ID: 9862768
    [Abstract] [Full Text] [Related]

  • 17. Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies.
    Shen Q, Li W, Lin Y, Katsumi H, Okada N, Sakane T, Fujita T, Yamamoto A.
    J Pharm Pharmacol; 2008 Dec 26; 60(12):1633-41. PubMed ID: 19000368
    [Abstract] [Full Text] [Related]

  • 18. Frog intestinal sac as an in vitro method for the assessment of intestinal permeability in humans: Application to carrier transported drugs.
    Franco M, Lopedota A, Trapani A, Cutrignelli A, Meleleo D, Micelli S, Trapani G.
    Int J Pharm; 2008 Mar 20; 352(1-2):182-8. PubMed ID: 18055143
    [Abstract] [Full Text] [Related]

  • 19. Marked impact of P-glycoprotein on the absorption of TAK-427 in rats.
    Takeuchi T, Nonaka M, Yoshitomi S, Higuchi T, Ebihara T, Maeshiba Y, Kawase M, Asahi S.
    Biopharm Drug Dispos; 2008 Sep 20; 29(6):311-23. PubMed ID: 18651556
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.